Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PPP5C | P53041 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.38 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25568891 | 0.94 | HTR1A (0.48) | HTR1ACYP1A2TDP1VNN1HSD11B1 | |
| SCHEMBL1561215 | 0.91 | LMNA (0.49) | HTR1ACYP1A2TDP1VNN1HSD11B1 | |
| SCHEMBL19012442 | 0.88 | MAPT (0.45) | HTR1ACYP1A2TDP1VNN1HSD11B1 | |
| SCHEMBL1561145 | 0.88 | HTR1A (0.43) | HTR1ACYP1A2TDP1VNN1HSD11B1 | |
| SCHEMBL31097151 | 0.82 | HPGD (0.43) | HSD11B1HTTALDH1A1 | |
| SCHEMBL24371412 | 0.81 | VNN1 (0.50) | HTR1ACYP1A2TDP1VNN1 | |
| SCHEMBL20346242 | 0.81 | HRH3 (0.47) | — | |
| SCHEMBL30967376 | 0.80 | ALDH1A1 (0.42) | HTR1AVNN1HSD11B1LMNAALDH1A1 | |
| SCHEMBL25568886 | 0.80 | HTR1A (0.43) | HTR1ACYP1A2TDP1VNN1HSD11B1 | |
| SCHEMBL1561876 | 0.80 | HTR1A (0.40) | HTR1ACYP1A2TDP1VNN1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HTR1A 2573/4885CYP1A2 3702/4885TDP1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.